P. Tassone

P. Tassone, P. Tagliaferri, V. Barbieri, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emerging Role of MicroRNAs in the Pathophysiology of Immune System

P. Tassone, P. Tagliaferri, M. Rossi, 2012 .

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis

P. Tassone, P. Tagliaferri, M. Caraglia, 2020, Cells.

Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.

P. Tassone, P. Tagliaferri, G. D’Arrigo, 2019, Molecular and clinical oncology.

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

P. Tassone, P. Tagliaferri, M. Caraglia, 2017, Journal of thoracic disease.

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

S. F. Carbone, P. Tassone, A. Abbruzzese, 2010, Cancer biology & therapy.

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics

M. Cannataro, P. Tassone, P. Tagliaferri, 2022, Biomedicines.

EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cells

M. Marra, P. Tassone, A. Abbruzzese, 2003, Cell Death and Differentiation.

Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis?

P. Tassone, P. Tagliaferri, G. Cuda, 2000, Lung cancer.

In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells

D. Carrasco, K. Anderson, N. Munshi, 2004, Cancer Research.

In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N-Deacetyl-N -(3-Mercapto-1-Oxopropyl)-Maytansine against CD56 Multiple Myeloma Cells

D. Carrasco, K. Anderson, N. Munshi, 2004 .

Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy.

M. Chatterjee, P. Tassone, T. Chakraborty, 2006, European journal of cancer.

Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths

C. D. Critello, P. Tassone, P. Tagliaferri, 2020, Frontiers in Bioengineering and Biotechnology.

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma

P. Tassone, P. Tagliaferri, G. Passarino, 2019, Cancers.

Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function.

P. Tassone, B. Quaresima, F. Costanzo, 2003, The Biochemical journal.

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.

D. Ribatti, D. Mangieri, P. Tassone, 2008, Blood.

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

A. Marchetti, F. Buttitta, M. Fassan, 2022, ESMO open.

Analysis of peripheral blood normal and malignant cells with the novel murine monoclonal antibody UN2.

P. Tassone, G. Morrone, M. Turco, 1994, Immunology letters.

Dysfunctional T regulatory cells in multiple myeloma.

N. Munshi, P. Tassone, D. Chauhan, 2006, Blood.

New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics

P. Tassone, P. Tagliaferri, M. Rossi, 2015 .

synergistic in myeloma cells hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are -tubulin α Aggresome induction by proteasome inhibitor bortezomib and

N. Munshi, P. Atadja, P. Tassone, 2013 .

Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.

N. Munshi, P. Tassone, R. Bronson, 2007, Experimental hematology.

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates

B. Nielsen, C. Mignogna, P. Tassone, 2016, Molecular therapy. Nucleic acids.

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

M. Cannataro, P. Guzzi, P. Tassone, 2013, Oncotarget.

Identiﬁcation of novel antigens with induced immune response in monoclonal gammopathy of undetermined signiﬁcance

N. Munshi, P. Tassone, C. Mitsiades, 2009 .

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.

N. Munshi, P. Tassone, C. Mitsiades, 2009, Blood.

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients

P. Tassone, P. Tagliaferri, C. Ulivieri, 2016, Oncoimmunology.

Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1

P. Tassone, C. Ambrosino, S. Venuta, 1993, Journal of virology.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories

A. Marchetti, F. Buttitta, P. Radice, 2019, Diagnostics.

The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells.

M. Marra, P. Tassone, A. Abbruzzese, 2003, Journal of biochemistry.

CD36 is rapidly and transiently upregulated on phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes. Analysis by a new monoclonal antibody (UN7).

P. Tassone, S. Venuta, V. Barbieri, 1998, Tissue antigens.

Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells

P. Tassone, S. Venuta, M. Romano, 1998 .

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma

P. Tassone, P. Tagliaferri, M. Arbitrio, 2022, International journal of molecular sciences.

Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia

G. Viglietto, N. Munshi, P. Tassone, 2022, Experimental Hematology & Oncology.

Mutation and Polymorphism Report

P. Tassone, B. Quaresima, F. Baudi, 1998 .

Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma

P. Tassone, A. Neri, M. Manzoni, 2018, Haematologica.

IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes.

P. Tassone, S. Venuta, M. Romano, 1996, Journal of immunology.

Telomerase Inhibition, Telomere Shortening and Apoptotic Cell Death in Multiple Myeloma Cells Following Exposure to a Novel and Potent Telomerase Inhibitor (GRN163L), Targeting RNA component of Telomerase.

N. Munshi, P. Tassone, M. Shammas, 2004 .

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice

P. Tassone, P. Tagliaferri, M. Arbitrio, 2020, Clinical and translational science.

CD69 expression on primitive progenitor cells and hematopoietic malignancies.

P. Tassone, S. Venuta, G. Morrone, 1996, Tissue antigens.

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach

P. Tassone, P. Tagliaferri, A. Giordano, 2022, Frontiers in Oncology.

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

P. Tassone, P. Tagliaferri, V. Barbieri, 2020, Frontiers in Oncology.

Partial purification and MALDI-TOF MS analysis of UN1, a tumor antigen membrane glycoprotein.

P. Tassone, S. Venuta, M. Masullo, 2006, International journal of biological macromolecules.

Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death.

P. Tassone, P. Tagliaferri, S. Venuta, 2002, European journal of cancer.

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma

N. Munshi, P. Tassone, P. Tagliaferri, 2016, Molecular Cancer Therapeutics.

Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors.

P. Tassone, S. Venuta, M. Romano, 1999, Blood.

Epstein-Barr VirusNuclear Antigen 2Transactivates theLong Terminal RepeatofHumanImmunodeficiency VirusType1

P. Tassone, C. Ambrosino, S. Venuta, 1993 .

Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.

P. Tassone, S. Venuta, M. Romano, 1998, Blood.

Triggering of CD 40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells

P. Tassone, S. Venuta, M. Romano, 1998 .

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

J. Kutok, Jiangwen Zhang, N. Munshi, 2007, Experimental hematology.

A SCID-hu in vivo model of human Waldenström macroglobulinemia.

J. Kutok, N. Munshi, P. Tassone, 2005, Blood.

Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer

P. Tassone, P. Tagliaferri, C. Botta, 2012, Oncoimmunology.

P. Tassone, P. Tagliaferri, C. Botta, 2012 .

Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

P. Tassone, M. Boccadoro, A. Neri, 2013, Clinical Cancer Research.

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients

G. Tonon, S. Bortoluzzi, G. Morgan, 2015, Oncotarget.

Immunologic microenvironment and personalized treatment in multiple myeloma

P. Tassone, P. Tagliaferri, C. Botta, 2013, Expert opinion on biological therapy.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

N. Munshi, P. Richardson, P. Tassone, 2007, Blood.

Molecular targets for the treatment of multiple myeloma.

P. Tassone, M. Caraglia, A. Grimaldi, 2012, Current cancer drug targets.

Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report

P. Tassone, P. Tagliaferri, V. Barbieri, 2022, Therapeutic advances in chronic disease.

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin

P. Tassone, P. Tagliaferri, F. Vasile, 2022, Journal of Translational Medicine.

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis

P. Tassone, P. Tagliaferri, M. Caraglia, 2021, Life.

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221

P. Tassone, P. Tagliaferri, C. Erratico, 2019, Cancers.

UN1, a murine monoclonal antibody recognizing a novel human thymic antigen.

P. Tassone, S. Venuta, G. Morrone, 1994, Tissue antigens.

A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells.

P. Tassone, S. Venuta, G. Morrone, 1994, Immunology Letters.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

P. Tassone, N. Raje, J. Duyster, 2018, Haematologica.

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

P. Tassone, P. Tagliaferri, A. Giordano, 2021, Journal for ImmunoTherapy of Cancer.

Novel hydroxamic acid-derived HDAC inhibitor LBH589 potently activates intrinsic and extrinsic apoptotic pathways, and induces tubulin hyperacetylation in multiple myeloma.

N. Munshi, P. Atadja, P. Tassone, 2005 .

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

F. Prósper, A. Órfão, N. Puig, 2019, Blood.

Transcriptional regulation of the mismatch repair gene hMLH1.

P. Tassone, G. Cuda, B. Quaresima, 2001, Gene.

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells

P. Tassone, P. Tagliaferri, S. Sestito, 2022, Cancers.

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

E. Wagner, D. Hose, H. Goldschmidt, 2021, Leukemia.

Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43

P. Tassone, F. Buonaguro, C. Palmieri, 2014, BioMed research international.

Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes

Massimo Fresta, Donatella Paolino, Roberto Molinaro, 2014, International journal of nanomedicine.

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives

P. Tassone, P. Tagliaferri, D. Caracciolo, 2023, Experimental Hematology & Oncology.

Mir-34: A New Weapon Against Cancer?

P. Tassone, P. Tagliaferri, M. Caraglia, 2014, Molecular therapy. Nucleic acids.

Mass Spectrometry-Based Identification Of The Tumor Antigen UN1 as the Transmembrane CD43 Sialoglycoprotein*

P. Tassone, M. Gaspari, M. Masullo, 2011, Molecular & Cellular Proteomics.

Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein.

P. Tassone, M. Gaspari, M. Masullo, 2011, Molecular & cellular proteomics : MCP.

Analysis of miRNA, mRNA, and TF interactions through network-based methods

Mario Cannataro, Pietro Hiram Guzzi, Maria Teresa Di Martino, 2015, EURASIP J. Bioinform. Syst. Biol..

New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer

M. Marra, P. Tassone, A. Abbruzzese, 2004, Cancer Immunology, Immunotherapy.

Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types

P. Tassone, E. Gaudio, G. Viola, 2020, Journal of medicinal chemistry.

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review

P. Tassone, P. Tagliaferri, M. Caraglia, 2023, La radiologia medica.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, N. Robert, M. Gnant, 2016, The Lancet. Oncology.

Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

M. Ferracin, M. Negrini, S. Molica, 2013, Clinical Cancer Research.

The improvement of flow cytometry techniques for the diagnosis of chronic lymphocytic 50 leukemia

M. Ferracin, M. Negrini, S. Molica, 2013 .

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy

P. Tassone, P. Tagliaferri, M. Arbitrio, 2021, Cancers.

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

G. Viglietto, N. Munshi, P. Tassone, 2020, Cancers.

Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing

P. Tassone, A. Neri, L. Agnelli, 2013, Expert opinion on biological therapy.

miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

P. Tassone, T. Calimeri, P. Tagliaferri, 2013, Cell cycle.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity

N. Munshi, P. Tassone, P. Tagliaferri, 2018, Leukemia.

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies

Marco Rossi, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2015, Oncotarget.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

E. Wagner, D. Hose, H. Goldschmidt, 2017, Leukemia.

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel

P. Tassone, P. Tagliaferri, D. Caracciolo, 2021, Cancers.

miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease

P. Tassone, P. Tagliaferri, M. Caraglia, 2013, Journal of cellular physiology.

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

P. Tassone, P. Tagliaferri, S. Pignata, 2016, Oncotarget.

lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome

S. Bicciato, P. Tassone, M. Colombo, 2016, Blood Cancer Journal.

A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells

P. Tassone, P. Tagliaferri, A. Giordano, 2014, Journal of cellular physiology.

Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers

C. Compton, C. Boland, M. Bertagnolli, 2004, International journal of cancer.

The oral protein-kinase C β inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines

S. Sacchi, M. Federico, P. Tassone, 2008, Leukemia & lymphoma.

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity

P. Tassone, P. Tagliaferri, A. Giordano, 2014, Oncotarget.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

N. Munshi, P. Tassone, P. Tagliaferri, 2018, Blood.

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

P. Tassone, P. Tagliaferri, D. Caracciolo, 2013, Current drug targets.

Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2013, Expert opinion on biological therapy.

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma

M. Negrini, P. Tassone, P. Tagliaferri, 2012, Oncotarget.

Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma

Massimo Fresta, Donatella Paolino, Donato Cosco, 2015, Scientific Reports.

Delivery of miR-34 a by chitosan / PLGA nanoplexes for anticancer treatment of multiple myeloma

P. Tassone, D. Paolino, M. Fresta, 2015 .

Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.

N. Munshi, P. Tassone, Y. Tai, 2012, Cancer genomics & proteomics.

Targeting PI 3 K and RAD 51 in Barrett ’ s Adenocarcinoma : Impact on DNA Damage Checkpoints , Expression Profile and Tumor Growth

N. Munshi, P. Tassone, Y. Tai, 2012 .

Long Noncoding RNA RROL Provides Chromatin Scaffold for MYC-WDR82 Interaction to Impact Lipid Metabolism and Tumor Cell Growth in Multiple Myeloma

Charles Y. Lin, M. Loda, N. Munshi, 2021, bioRxiv.

Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma

P. Tassone, A. Neri, M. Manzoni, 2019, Leukemia.

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

P. Tassone, J. Fridman, D. Chauhan, 2009, Molecular Cancer Therapeutics.

Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma

N. Munshi, R. Savino, P. Tassone, 2005, Clinical Cancer Research.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study

Mario Cannataro, Giuseppe Agapito, Mariamena Arbitrio, 2019, Clinical pharmacology and therapeutics.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2016, Oncotarget.

Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study

Mario Cannataro, Pietro Hiram Guzzi, Mariamena Arbitrio, 2011, Cancer biology & therapy.

Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”

P. Guzzi, P. Tassone, P. Tagliaferri, 2020, Journal of experimental & clinical cancer research : CR.

Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells

G. Viglietto, P. Tassone, A. Neri, 2021, International journal of molecular sciences.

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma

P. Tassone, A. Neri, M. Manzoni, 2020, Cancers.

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells

N. Munshi, P. Tassone, P. Tagliaferri, 2015, Clinical Cancer Research.

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias

G. Tonon, E. Pinatel, P. Tassone, 2015, Oncotarget.

The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma

P. Tassone, A. Neri, M. Ferrarini, 2012, Blood Cancer Journal.

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

M. Negrini, N. Munshi, P. Tassone, 2012, Clinical Cancer Research.

Alternative non-homologous end joining repair: a master regulator of genomic instability in cancer

P. Tassone, P. Tagliaferri, D. Caracciolo, 2019, Precision Cancer Medicine.

Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

N. Munshi, P. Tassone, P. Tagliaferri, 2013, Clinical Cancer Research.

NF-κB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors

P. Tassone, S. Venuta, M. Romano, 2004, Leukemia.

Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-κB/Rel− specific decoy oligodeoxynucleotides

P. Tassone, S. Venuta, M. Romano, 2000, Gene Therapy.

LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?

P. Tassone, A. Neri, N. Amodio, 2020, Non-coding RNA.

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

C. Boland, P. Tassone, P. Tagliaferri, 2003, British Journal of Cancer.

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy

G. Baio, M. Negrini, M. Cilli, 2017, Leukemia.

Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

P. Tassone, P. Neri, L. Boise, 2011, Blood.

Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?

R. Terracciano, P. Tassone, P. Tagliaferri, 2006, European journal of cancer.

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

N. Munshi, P. Tassone, Shaji K. Kumar, 2005, Blood.

[4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth In vitro and in vivo activity of atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro

N. Munshi, P. Richardson, P. Tassone, 2005 .

Identification by Differential Display of Transcripts Regulated during Hematopoietic Differentiation

L. Iacopino, P. Tassone, F. Costanzo, 1998, Stem cells.

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).

N. Munshi, P. Richardson, P. Tassone, 2004, Blood.

Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation

P. Tassone, P. D’Aquila, G. Passarino, 2017, Expert opinion on therapeutic targets.

Integration of DNA Microarray with Clinical and Genomic Data.

P. Tassone, P. Tagliaferri, M. Arbitrio, 2021, Methods in molecular biology.

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2020, Haematologica.

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

N. Munshi, P. Tassone, D. Chauhan, 2007, Blood.

Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

P. Tassone, P. Tagliaferri, C. Botta, 2013 .

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.

P. Tassone, P. Tagliaferri, M. Arbitrio, 2018, Critical reviews in oncology/hematology.

The potential role of miRNAs in multiple myeloma therapy

P. Tassone, P. Tagliaferri, D. Caracciolo, 2018, Expert review of hematology.

MicroRNAs in multiple myeloma and related bone disease.

P. Tassone, P. Tagliaferri, M. Rossi, 2015, Annals of translational medicine.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling

P. Tassone, P. Tagliaferri, F. Cirillo, 2018, Journal of experimental & clinical cancer research : CR.

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse

P. Tassone, P. Tagliaferri, M. Caraglia, 2016, Cancer biology & therapy.

Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation.

P. Tassone, P. Tagliaferri, N. Amodio, 2018, Current medicinal chemistry.

Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro

P. Tassone, P. Tagliaferri, M. Caraglia, 2014, Cancer biology & therapy.

Precision Oncology: Present Status and Perspectives

Maria Teresa Di Martino, Pierosandro Tagliaferri, Mariamena Arbitrio, 2017 .

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.

P. Tassone, P. Tagliaferri, M. Caraglia, 2013, European journal of cancer.

Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress–Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response

P. Tassone, L. Pinna, M. Ruzzene, 2012, Clinical Cancer Research.

A clinically relevant SCID-hu in vivo model of human multiple myeloma.

Pierfrancesco Tassone, Salvatore Venuta, D. Carrasco, 2004, Blood.

Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters

P. Tassone, P. Tagliaferri, M. Arbitrio, 2021 .

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine

P. Tassone, S. Zappavigna, P. Tagliaferri, 2018, Oncotarget.

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

S. Lonial, P. Tassone, P. Neri, 2010, Blood.

microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters

M. Ferracin, S. Sabbioni, G. Calin, 2014, Clinical Cancer Research.

Biology of Human Tumors microRNAome Expression in Chronic Lymphocytic Leukemia : Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters

M. Ferracin, S. Sabbioni, G. Calin, 2014 .

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

P. Tassone, P. Tagliaferri, M. Gaspari, 2020, Leukemia.

The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate

M. Marra, P. Tassone, A. Abbruzzese, 2004, Oncogene.

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma

P. Tassone, P. Tagliaferri, M. Caraglia, 2019, Molecular therapy. Nucleic acids.

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

N. Munshi, P. Tassone, T. Calimeri, 2011, Leukemia.

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

P. Tassone, T. Calimeri, P. Tagliaferri, 2009, Cancer biology & therapy.

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment

P. Tassone, N. Amodio, L. Raimondi, 2017, Oncotarget.

Identification of SET/EED dual binders as innovative PRC2 inhibitors.

P. Tassone, S. Alcaro, G. Costa, 2022, Future medicinal chemistry.

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.

P. Tassone, P. Tagliaferri, C. Botta, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)

P. Tassone, S. Zappavigna, P. Tagliaferri, 2017, Oncotarget.

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

N. Munshi, P. Tassone, P. Tagliaferri, 2016, Molecular cancer therapeutics.

In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor

P. Tassone, T. Calimeri, P. Tagliaferri, 2008, British journal of haematology.

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

N. Munshi, P. Tassone, S. Treon, 2014, Blood.

in Waldenström macroglobulinemia MYD88-independent growth and survival effects of Sp1 transactivation

P. Tassone, S. Treon, Z. Hunter, 2014 .

Waldenstrom ' s macroglobulinemia MYD 88-independent growth and survival effects of Sp 1 transactivation in

N. Munshi, P. Tassone, S. Treon, 2014 .

LYMPHOID NEOPLASIA MYD 88-independent growth and survival effects of Sp 1 transactivation in Waldenström macroglobulinemia

N. Munshi, P. Tassone, S. Treon, 2014 .

Challenges in Multiple Myeloma Chemoprevention: Potential Role of Natural, Synthetic and Endogenous Molecules

P. Tassone, E. Morelli, N. Amodio, 2016 .

Circulating MicroRNA Profiling in Cancer Biomarker Discovery

P. Tassone, P. Tagliaferri, F. Scionti, 2018, Biomarker - Indicator of Abnormal Physiological Process.

In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells

N. Munshi, P. Tassone, N. Raje, 2006, British journal of haematology.

Multiple myeloma-related bone disease: state-of-art and next future treatments

P. Tassone, T. Calimeri, P. Tagliaferri, 2015 .

Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia

M. Ferracin, M. Negrini, S. Molica, 2015, Leukemia & lymphoma.

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment

P. Tassone, P. Tagliaferri, E. Morelli, 2016, BioMed research international.

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

M. Marra, P. Tassone, A. Abbruzzese, 2010, European journal of cancer.

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

P. Tassone, Y. Bang, Yoon-Koo Kang, 2014, British Journal of Cancer.

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma

Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Kemal Samur, 2017, Leukemia.

Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma

N. Munshi, P. Richardson, P. Tassone, 2004, Cancer Research.

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities

P. Tassone, P. Tagliaferri, A. Gullà, 2014, Front. Oncol..

Emerging pathways as individualized therapeutic target of multiple myeloma

Michele Caraglia, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2013, Expert opinion on biological therapy.

Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials.

P. Tassone, A. Abbruzzese, P. Tagliaferri, 2012, Oncology reports.

Immunotherapy of colorectal cancer: new perspectives after a long path.

P. Tassone, S. Zappavigna, P. Tagliaferri, 2016, Immunotherapy.

Specific Killing of Multiple Myeloma Cancer Cells by Epigallocatechin-3-Gallate Extracted from Green Tea.

N. Munshi, P. Tassone, R. Batchu, 2004 .

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

P. Tassone, P. Tagliaferri, V. Barbieri, 2019, Journal of Hematology & Oncology.

Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues.

P. Tassone, S. Venuta, G. Morrone, 1998, Tissue antigens.

347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

M. Piccart, H. Wildiers, P. Tassone, 2020 .

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Cancers.

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

P. Tassone, P. Tagliaferri, M. Caraglia, 2020, Journal for immunotherapy of cancer.

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

P. Tassone, P. Tagliaferri, M. Caraglia, 2015, Cancer biology & therapy.

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

H. Goldschmidt, N. Puig, P. Tassone, 2021, Blood advances.

B R I E F C O M M U N I C a T I O N Open Access

R. Franco, C. Mignogna, P. Tassone, 2022 .

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

P. Tassone, P. Tagliaferri, A. Giordano, 2015, Oncotarget.

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

D. Carrasco, N. Munshi, P. Tassone, 2004, Blood.

Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation

P. Tassone, N. Amodio, R. Giardino, 2015, Oncotarget.

Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma

N. Munshi, P. Tassone, R. Batchu, 2007, Leukemia.

Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data

Mario Cannataro, Giuseppe Agapito, Mariamena Arbitrio, 2021, J. Comput. Sci..

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

P. Tassone, P. Tagliaferri, M. Caraglia, 2013, Journal of drug delivery.

Multiple Myeloma - a New Era of Treatment Strategies

G. Tonon, S. Lonial, D. Ribatti, 2012 .

Automatic summarisation and annotation of microarray data

Mario Cannataro, Pietro Hiram Guzzi, Giuseppe Tradigo, 2011, Soft Comput..

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment

P. Tassone, S. Zappavigna, P. Tagliaferri, 2017, Scientific Reports.

Human Hematopoietic Cells Expression of the Wiskott-Aldrich Syndrome Protein (WASP) Gene in Regulatory Sequence Containing Two Ets Motifs Controls the ' A 5

P. Tassone, A. Petrella, V. Agosti, 2013 .

A 5' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells.

A. Ballabio, P. Tassone, S. Venuta, 1998, Blood.

A 5 8 Regulatory Sequence Containing Two Ets Motifs Controls the Expression of the Wiskott-Aldrich Syndrome Protein ( WASP ) Gene in Human Hematopoietic Cells

A. Ballabio, P. Tassone, S. Venuta, 1998 .

Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma

P. Tassone, P. Tagliaferri, M. Caraglia, 2014, BioMed research international.

Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling

G. Viglietto, P. Tassone, P. Tagliaferri, 2020, ACS omega.

Mir-221/222 are promising targets for innovative anticancer therapy

Marco Rossi, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2016, Expert opinion on therapeutic targets.

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Journal of Experimental & Clinical Cancer Research.

miR-22 suppresses DNA ligase III addiction in multiple myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2018, Leukemia.

Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model

N. Munshi, P. Tassone, Shaji K. Kumar, 2007, Clinical Cancer Research.

The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.

P. Tassone, P. Tagliaferri, S. Venuta, 2002, International journal of oncology.

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

P. Tassone, P. Tagliaferri, M. Arbitrio, 2022, Molecular therapy. Nucleic acids.

Functional Analysis of microRNA in Multiple Myeloma.

P. Tassone, P. Tagliaferri, N. Amodio, 2016, Methods in molecular biology.

In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma

M. Cannataro, R. Franco, P. Guzzi, 2014, PloS one.

Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

Mario Boccadoro, Pierfrancesco Tassone, Laura Mosca, 2013, Clinical Cancer Research.

MicroRNAs in the pathobiology of multiple myeloma.

P. Tassone, A. Neri, L. Agnelli, 2012, Current cancer drug targets.

In Vitro Silencing of lncRNAs Using LNA GapmeRs.

G. Viglietto, N. Munshi, P. Tassone, 2021, Methods in molecular biology.

Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.

N. Munshi, P. Richardson, P. Tassone, 2004 .

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2019, Cancers.

Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

P. Tassone, P. Tagliaferri, M. Caraglia, 2016, Current drug targets.

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

A. Marchetti, P. Radice, P. Tassone, 2016, Future oncology.

In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

P. Tassone, T. Calimeri, P. Tagliaferri, 2009, Cancer Chemotherapy and Pharmacology.

Monoclonal Antibody–Based Therapies in Human Multiple Myeloma

N. Munshi, P. Richardson, P. Tassone, 2009 .

The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro‐apoptotic activity of interferon‐α through the inhibition of multiple survival pathways

M. Marra, P. Tassone, A. Abbruzzese, 2007, International journal of cancer.

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials

P. Tassone, P. Tagliaferri, M. Rotundo, 2016, Oncotarget.

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

P. Tassone, P. Tagliaferri, D. Caracciolo, 2023, Journal of Translational Medicine.

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease

P. Tassone, P. Bedossa, A. Sanyal, 2020, Scientific Reports.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2015, Cancer Chemotherapy and Pharmacology.

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2021, Cancers.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2017, Oncotarget.

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

A. Rossi, C. Gridelli, P. Tassone, 2013, Cancer biology & therapy.

Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.

M. Marra, P. Tassone, A. Abbruzzese, 2009, Current cancer drug targets.

Role of P 53 and Ki-67 as Prognostic Factors in Ovarian Cancer : Systematic Review and Pooled-Analysis

Tagliaferri, P. Tassone, D. Ciliberto, 2018 .

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

A. Marchetti, F. Buttitta, P. Radice, 2019, Critical reviews in oncology/hematology.

A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).

P. Tassone, D. Galetta, S. Novello, 2017 .

Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS.

P. Tassone, P. Tagliaferri, M. Arbitrio, 2020, Journal of pharmaceutical and biomedical analysis.

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats

P. Tassone, P. Tagliaferri, M. Arbitrio, 2020, Molecular therapy. Nucleic acids.

MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.

P. Tassone, P. Tagliaferri, W. Cho, 2014, Current pharmaceutical biotechnology.

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Mariamena Arbitrio, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2009, Journal of ovarian research.

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

P. Tassone, P. Tagliaferri, D. Caracciolo, 2017, Current cancer drug targets.

The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells

G. Pinkus, Jian-jun Zhao, Catherine J. Wu, 2015, Nature Medicine.

Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients

P. Tassone, A. Abbruzzese, P. Tagliaferri, 2012, Journal of immunotherapy.

A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.

P. Tassone, P. Tagliaferri, D. Caracciolo, 2019, European journal of medicinal chemistry.

O-0021PERTUZUMAB PHARMACOKINETICS AND SAFETY IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED GASTRIC CANCER (AGC)

P. Tassone, Y. Bang, Yoon-Koo Kang, 2013 .

DMETTM Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2020, High-throughput.

The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy

G. Pinkus, Jian-jun Zhao, Catherine J. Wu, 2015, Nature medicine.

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

P. Tassone, P. Tagliaferri, C. Botta, 2013, Journal of Ovarian Research.

Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.

P. Tassone, P. Tagliaferri, S. Venuta, 2007, Current pharmaceutical design.

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Frontiers in oncology.

Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.

P. Tassone, T. Calimeri, A. Abbruzzese, 2009, Current cancer drug targets.

The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways (International Journal of Cancer (2007) 121, (2317-2330))

M. Marra, P. Tassone, A. Abbruzzese, 2008 .

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

N. Munshi, P. Tassone, P. Tagliaferri, 2012, Cell Death and Disease.

Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia

P. Tassone, P. Tagliaferri, F. Morabito, 2014, Leukemia & lymphoma.

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro

C. Boland, P. Tassone, A. Abbruzzese, 2003, British Journal of Cancer.

1439 POSTER Treatment-related Changes in Systemic Inflammatory Status, Measured by Neutrophil-to-lymphocyte Ratio, is Predictive of Outcome in Metastatic Colorectal Cancer Patients

P. Tassone, P. Tagliaferri, B. Vincenzi, 2011 .

1418 POSTER Baseline Inflammatory Status Defined by Neutrophil to Lymphocyte Cell Count Ratio (NLR) Predicts Progression Free Survival (PFS) in Metastatic Colorectal Cancer Patients (mCRC) Undergoing Bevacizumab Based Biochemotherapy

P. Tassone, P. Tagliaferri, B. Vincenzi, 2011 .

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer

P. Tassone, P. Tagliaferri, M. Caraglia, 2020, Translational lung cancer research.

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

P. Tassone, P. Tagliaferri, T. Giudice, 2012 .

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

P. Tassone, P. Tagliaferri, V. Barbieri, 2023, Journal of Hematology & Oncology.

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

P. Tassone, A. Neri, E. Leone, 2012, Current cancer drug targets.

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers

Daniele Caracciolo, Marzia Settino, Mario Cannataro, 2020, ICCS.

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2016, Microarrays.

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice

P. Tassone, P. Tagliaferri, G. Caridà, 2023, Cancers.

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients

P. Tassone, P. Tagliaferri, M. Caraglia, 2016, Cell Death Discovery.

Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas.

F. D'armiento, P. Tassone, P. Tagliaferri, 2002, Anticancer Research.

Fetal ontogeny and tumor expression of the early thymic antigen UN1.

F. D'armiento, P. Tassone, S. Venuta, 2002, International Journal of Oncology.

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis

P. Tassone, P. Tagliaferri, C. Riillo, 2023, Heliyon.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling

Pierosandro Tagliaferri, Pierfrancesco Tassone, Maria Teresa Di Martino, 2018, Journal of Experimental & Clinical Cancer Research.

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment

P. Tassone, S. Zappavigna, P. Tagliaferri, 2017, Scientific Reports.

Detection of an antigenic marker expressed by peripheral blood monocytes and platelets by a new monoclonal antibody, UN8.

P. Tassone, S. Venuta, G. Morrone, 1995, Tissue antigens.

A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth.

Charles Y. Lin, M. Loda, N. Munshi, 2022, Blood.

Hit identification of novel small molecules interfering with MALAT1 triplex by a structure‐based virtual screening

P. Tassone, B. Pagano, Jussara Amato, 2023, Archiv der Pharmazie.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival

P. Tassone, P. Tagliaferri, C. Botta, 2016, Blood Cancer Journal.

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response

P. Tassone, P. Tagliaferri, M. Caraglia, 2016, Cell Death and Disease.

6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results F

P. Tassone, P. Tagliaferri, A. Guglielmo, 2011 .

Effects of the indazolylpyrimidine GW786034 on angiogenesis and MM cell growth: Therapeutic implications.

P. Tassone, Shaji K. Kumar, D. Chauhan, 2004 .

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

N. Munshi, C. Mignogna, P. Tassone, 2017, Leukemia.

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease

P. Tassone, P. Bedossa, A. Sanyal, 2020, Scientific Reports.

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies

P. Tassone, P. Tagliaferri, N. Amodio, 2015, Oncotarget.

A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Michael L. Wang, S. Jagannath, N. Munshi, 2005 .

Targeting non-coding RNAs: Perspectives and challenges of in-silico approaches.

P. Tassone, P. Tagliaferri, S. Alcaro, 2023, European journal of medicinal chemistry.

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

P. Tassone, P. Tagliaferri, M. Caraglia, 2012, Current cancer drug targets.

Single-Cell Characterization of Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-negative T cells as Potential Tumor-Reactive Lymphocytes

Cristina Pérez Ruiz, F. Prósper, A. Órfão, 2019, Clinical Lymphoma Myeloma and Leukemia.

The impact of PARP inhibitors in the whole scenario of Ovarian Cancer management: a Systematic Review and Network Meta-Analysis.

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Critical reviews in oncology/hematology.

M. Cannataro, P. Guzzi, P. Tassone, 2011, British journal of haematology.

Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.

P. Tassone, P. Tagliaferri, B. Quaresima, 2005, International journal of oncology.

Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

P. Tassone, M. Boccadoro, A. Neri, 2013, Clinical Cancer Research.

Biological and Clinical Relevance of Mirna Expression Signatures in Primary Plasma Cell Leukemia Translational Relevance

Milan, P. Tassone, M. Boccadoro, 2022 .

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

P. Tassone, P. Tagliaferri, V. Martinelli, 2000, Leukemia.

Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

M. Ferracin, M. Negrini, S. Molica, 2013, Clinical Cancer Research.

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.

N. Munshi, P. Richardson, P. Tassone, 2005, Blood.

Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma

P. Tassone, A. Neri, M. Manzoni, 2019, Leukemia.

Overall Survival Analyzer: A software tool to analyze genotyping and clinical data enriched with temporal events

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2015, 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).

Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs

P. Tassone, T. Calimeri, P. Tagliaferri, 2014 .

Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma.

P. Tassone, P. Tagliaferri, A. Neri, 2016, Molecular cancer therapeutics.

Personalized Medicine

P. Tassone, P. Tagliaferri, 2021, Practical Medical Oncology Textbook.

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

A. Marchetti, P. Radice, P. Tassone, 2016, Future oncology.

NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors.

P. Tassone, S. Venuta, M. Romano, 2004, Leukemia.